iOnctura's roginolisob has potential for patients with solid and hematological tumors 21-Mar-2023 By Liza Laws Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.
Global 'Cancer Grand Challenges' initiative outlines nine toughest challenges to tackling the disease 15-Mar-2023 By Ben Hargreaves A research initiative co-led by Cancer Research UK and the National Cancer Institute announces funding to tackle core challenges in cancer treatment.
Bayer to commercialize TRK inhibitor as Roche creates competition 21-Feb-2019 By Maggie Lynch Bayer exercises its option to obtain exclusive licensing rights for the global development and commercialization of Loxo Oncology’s solid tumor drugs.